You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
|
|---|---|
| Published in |
BMC Cancer, August 2014
|
| DOI | 10.1186/1471-2407-14-592 |
| Pubmed ID | |
| Authors |
Benjamin Haaland, Akhil Chopra, Sanchalika Acharyya, André P Fay, Gilberto de Lima Lopes |
| Abstract |
Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate risk metastatic clear cell renal cell carcinoma (mRCC). However, there is little comparative data to help in choosing the most effective drug among these agents. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Mexico | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 4% |
| Portugal | 1 | 2% |
| Unknown | 42 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 22% |
| Student > Master | 6 | 13% |
| Student > Bachelor | 4 | 9% |
| Student > Ph. D. Student | 4 | 9% |
| Lecturer | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 13 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 44% |
| Agricultural and Biological Sciences | 4 | 9% |
| Nursing and Health Professions | 3 | 7% |
| Computer Science | 2 | 4% |
| Economics, Econometrics and Finance | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 13 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 August 2014.
All research outputs
#14,198,795
of 22,760,687 outputs
Outputs from BMC Cancer
#3,353
of 8,277 outputs
Outputs of similar age
#118,961
of 230,675 outputs
Outputs of similar age from BMC Cancer
#62
of 159 outputs
Altmetric has tracked 22,760,687 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,277 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 230,675 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 159 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.